Alcohol-induced liver disease: primary and secondary prevention
Abstract
The aim of review. To keep doctors and population in the picture of alcohol abuse issues and to acquaint with treatment approach at alcoholic disease, to prove necessity of primary and secondary prophylaxis.
Key points. Alcoholism control efforts should be directed first of all on prevention of this disease. Primary prophylaxis is necessary for decrease or stop of alcohol consumption. It is required to educate population and to unveil myths about safe, and the more so useful dozes of alcohol. Secondary prophylaxis includes application of specific therapy with application of metabolic agents (hepatoprotectors).
Conclusion. Alcohol is the main etiological factor of liver cirrhosis in Russia. Prompt change of situation with alcohol abuse is required for reduction of morbidity and mortality. Preventive actions should be directed on change of embedded stereotypes of doctors and population in relation to alcohol intake.
About the Authors
S. V. Plyusnin
Vishnevsky Central Military Clinical Hospital
Russian Federation
Russian Federation
Plyusnin Sergey V — MD, PhD, professor
K. V. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
A. N. Bobrov
Vishnevsky Central Military Clinical Hospital
Russian Federation
Russian Federation
S. A. Belyakin
Vishnevsky Central Military Clinical Hospital
Russian Federation
Russian Federation
I. V. Plyusnina
Vishnevsky Central Military Clinical Hospital
Russian Federation
Russian Federation
References
1. European Detailed Mortality Database (http://data.euro. who.int/dmdb/).
2. Бобров А.Н., Белякин С.А., Плюснин С.В. Этиологическая структура циррозов печени по результатам пятнадцатилетнего наблюдения. Вестник Российской Военно-медицинской академии 2011; 1:76-81.
3. Белякин С.А., Бобров А.Н., Плюснин С.В. Взаимозависимость употребления алкоголя и смертности от цирроза печени. Воен-мед журн 2009; 330(9):48-54.
4. Хазанов А.И. Из полувекового опыта наблюдения за больными циррозом печени. Рос журн гастроэнтерол гепатол колопроктол 1998; 8(2):50-60.
5. Ramstedt M. Per capita alcohol consumption and liver cirrhosis mortality in 14 European countries. Addiction 2001; 96(1):19-33.
6. Боткин С.П. Курс клиники внутренних болезней и клинические лекции. Медгиз, 1950; 1:181.
7. Edwards G., Anderson P. , Babor T.F. Alcohol policy and the public good. Oxford: University Press, 1995; 240.
8. Rehm J., Taylor B., Mohapatra S., Irving H., Baliunas D., Patra J. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev 2010; 29:437-45.
9. Bressa G.M. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994; 154:7-14.
10. Mato J.M., Camara J., Caballeria L. S-adenosylmethionine in alcoholic liver cirrhosis: placebo-controlled, doubleblind, multicentre clinical trial. J Hepatol 1999; 30:1081-9.
11. Рapakostas G.I., Mischoulon D., Shyu I., Alpert J.E., Fava M. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167:942-8.
12. Salmaggi P., Bressa G.M., Nicchia G., et al. Doubleblind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993; 59:34-40.
13. Lieber C.S., Robins S.J., Li J. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterol 1994; 106:152-9.
14. Rambaldi A., Bradly P.J., Iaquinto G. Milk thistle for alcoholic and/or hepatitis B or C liver diseases — a systematic Cochrane hepato-biliary group review with metaanalyses of randomized clinical trials. Am J Gastroenterol 2005; 100(11):2583-91.
15. Saller R., Brignoli R., Melzer J., Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15(1):9-20.
16. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61(14):2035-63.
17. Trinchet J.C., Coste T., Levy V.G. Treatment of alcoholic hepatitis with silymarin. A double blind comparative study in 116 patients. Gastroenterol Clin Biol 1989; 13(4):120-4.
18. Bai Ming, Zhiping Yang, Xingshun Qi. L-ornithineL-aspartate for hepatic encephalopathy in patients with cirrhosis: meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28(5):783-92.
19. Gluud C., Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2001; 4.
20. Lieber C.S., Weiss D.G., Groszmann R., Paronetto F. Veterans affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003; 27(11):1765-72.
21. Pares А., Planas Р., Torres М. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled double-blind randomized and multicenter trial. J Hepatol 1998; 28:615-21.
Review
For citations:
Plyusnin S.V., Ivashkin K.V., Bobrov A.N., Belyakin S.A., Plyusnina I.V. Alcohol-induced liver disease: primary and secondary prevention. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(3):42-48. (In Russ.)
Views:
158
Email this article 
